Pharmaceutical

Study links insulin therapy to bladder cancer deaths in diabetics

actos pioglitazone hydrochloride Study links insulin therapy to bladder cancer deaths in diabeticsType 2 diabetics on insulin therapy are more likely to die from bladder cancer than those using other treatments, a new study suggests.

Researchers with the Department of Internal Medicine at the National Taiwan University College of Medicine in Taipei, followed more than 86,000 patients with type 2 diabetes aged 25 or older from 1995 through 2006 for bladder cancer deaths. They concluded that patients who used insulin to keep their blood sugar levels in check were nearly twice as likely to die from bladder cancer compared to those who did not use insulin.

Patients who used insulin and who smoked tobacco were three times as likely to die from bladder cancer. Older men who smoked and used insulin over a long period of time were at the greatest risk of dying from bladder cancer.

In 2011, the Food and Drug Administration (FDA) warned that studies indicated that the type 2 diabetes drug Actos increased the risk of bladder cancer, especially in those who used the drug long-term.

Researchers concluded that patients with type 2 diabetes may fare better using other forms of diabetes treatments. However, other medications to treat the chronic condition carry similar risks.

More recent studies have raised concerns about newer diabetes medications. Earlier this year, studies on a class of diabetes drugs known as incretin mimetics were linked to problems with the pancreas. The drugs in this class that raised the most concern include Januvia and Byetta. Futher studies showed the drugs increased the risk for acute pancreatitis and abnormal cell growth in the pancreas which could lead to pancreatic cancer.

Source: Food Consumer